Network Version
Triclabendazole Data Sheet
| Product Name: | Triclabendazole |
 |
|---|---|---|
| CAS No.: | 68786-66-3 | |
| Cat. No.: | HY-B0621 | |
| MWt: | 359.66 | |
| Formula: | C14H9Cl3N2OS | |
| Purity : | >98% | |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) | |
| Mechanisms: | Target: Infection | |
| Biological Activity: | ||
|
Triclabendazole is an orally active parasite inhibitor. Triclabendazole has anti-Leishmania activity and induces gasdermin E (GSDME)-dependent pyroptosis by caspase-3 activation. Triclabendazole can be used for the research of fasciola hepatica[1][2][3].
In Vitro:Triclabendazole (20-320 μM, 24-48 h) has cytotoxicity on MCF-7 and MDA-MB-231 cells[1]. Triclabendazole (40-160 μM, 24 h) induces apoptosis in MCF-7 and MDA-MB-231 cells[1]. Triclabendazole (0.97-500 μM, 48-72 h) have low cytotoxicity in Macrophages[3]. Triclabendazole (45.67 μM, 72 h) shows significant alterations in cell cycle with a decrease in G1 from 74.6% to 54.3% and an increase in S and G2 from 9.7% to 16.6% and 11.9% to 25.4%, respectively phases in promastigotes[3]. In Vivo:Triclabendazole (20-100 mg/kg, Intraperitoneal injection, twice a week for 2 weeks) has anti-tumor effect in the xenograft MDA-MB-231 cells model nude mice[1]. |
||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com